Research programme: oncolytic virus cancer therapeutics - DNAtrix

Drug Profile

Research programme: oncolytic virus cancer therapeutics - DNAtrix

Alternative Names: Delta 24 ACT; Delta-24-RGDOX; DNX-2440; DNX-2450; MYX-135

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DNAtrix
  • Class Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Solid tumours
  • Research Haematological malignancies

Most Recent Events

  • 13 Nov 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 13 Nov 2017 DNAtrix plans a clinical trial of DNX 2440 for solid tumours
  • 08 Nov 2016 DNAtrix in-licenses myxoma oncolytic virus platform from University of Florida
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top